Publicaciones en colaboración con investigadores/as de Columbia University (25)

2024

  1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  2. Sex dependence of postoperative pulmonary complications – A post hoc unmatched and matched analysis of LAS VEGAS

    Journal of Clinical Anesthesia, Vol. 99

2023

  1. Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis

    Gynecologic Oncology, Vol. 177, pp. 157-164

  2. Neurobiology of eating behavior, nutrition, and health

    Journal of Internal Medicine, Vol. 294, Núm. 5, pp. 582-604

  3. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

    Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60

  4. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

    Genome Medicine, Vol. 15, Núm. 1

2022

  1. Association of Prenatal Exposure to Endocrine-Disrupting Chemicals with Liver Injury in Children

    JAMA Network Open, Vol. 5, Núm. 7, pp. E2220176

  2. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease

    Gut, Vol. 71, Núm. 9, pp. 1856-1866

  3. Genomic profiling for clinical decision making in lymphoid neoplasms

    Blood

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Prenatal and childhood exposure to air pollution and traffic and the risk of liver injury in European children

    Environmental Epidemiology, Vol. 5, Núm. 3

  3. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

    Blood Cancer Journal, Vol. 11, Núm. 12

  4. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e119-e130

  5. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

2020

  1. A roadmap for the development of ivermectin as a complementary malaria vector control tool

    American Journal of Tropical Medicine and Hygiene, Vol. 102, pp. 3-24

2019

  1. Cohort profile: Design and methods of the PREDIMED-Plus randomized trial

    International Journal of Epidemiology, Vol. 48, Núm. 2, pp. 387-388o

2018

  1. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis

    Journal of Hepatology, Vol. 69, Núm. 2, pp. 396-405

2017

  1. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    The Lancet, Vol. 390, Núm. 10094, pp. 555-566

2016

  1. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557

  2. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    The Lancet Oncology, Vol. 17, Núm. 8, pp. e328-e346